LNTH News

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Connect

PharmaLogic Announces Successful Supply of First Cohort Dosing for Ratio Therapeutics' Phase 1/2 Study of a Novel FAP-Targeted Radiopharmaceutical in Late-Stage Aggressive Sarcomas

Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas

Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Shareholders to Reach Out

Lifshitz Law PLLC Announces Investigations of Cytokinetics, Incorporated (NASDAQ: CYTK), Fly-E Group, Inc. (NASDAQ: FLYE), Lantheus Holdings, Inc. (NASDAQ: LNTH), and Savara Inc. (NASDAQ: SVRA)

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Stockholders to Inquire about Securities Investigation